載入...
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8(+) T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. O...
Na minha lista:
| 發表在: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society for Clinical Investigation
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773365/ https://ncbi.nlm.nih.gov/pubmed/32990678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI140837 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|